#AUA14 - Poster: Impact of prior endocrine therapy on clinical benefit of abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302

ORLANDO, FL USA (UroToday.com) - Presented by Fred Saad,¹ Thian Kheoh,² Margaret K. Yu,² Matthew R. Smith,³ Eric J. Small,⁴ Peter F.A. Mulders,⁵ Karim Fizazi,⁶ Dana E. Rathkopf,⁷ Stéphane Oudard,⁸ Howard I. Scher,⁷ Joaquim Bellmunt,⁹ Mary-Ellen Taplin,⁹ Ian D. Davis,¹⁰ Dirk Schrijvers,¹¹ Andrew Protheroe,¹² Arturo Molina,¹³ Thomas W. Griffin,² Johann S. de Bono,¹⁴ and Charles J. Ryan⁴ at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

¹University of Montréal, Montréal, QC, Canada; ²Janssen Research & Development, Los Angeles, CA; ³Harvard Medical School and Massachusetts General Hospital, Boston, MA; ⁴Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; ⁵Radboud University Medical Centre, Nijmegen, The Netherlands; ⁶Institut Gustave Roussy, University of Paris Sud, Villejuif, France; ⁷Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; ⁸Georges Pompidou Hospital, Paris, France; ⁹Dana-Farber Cancer Institute, Boston, MA; ¹⁰Monash University and Eastern Health, Victoria, Australia; ¹¹ZNA Middelheim Oncology Clinic, Antwerp, Belgium; ¹²Churchill Hospital, Oxford, United Kingdom; ¹³Janssen Research & Development, Menlo Park, CA; ¹⁴The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, United Kingdom

Click HERE to read an exclusive report by a UroToday medical writer